Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations

Nature Genetics

Volumn 47, Issue 8, 2015, Pages 864-871

  Eleveld, Thomas F ^a   Oldridge, Derek A ^b,c   Bernard, Virginie ^d   Koster, Jan ^a   Daage, Leo Colmet ^d   Diskin, Sharon J ^b,c   Schild, Linda ^a   Bentahar, Nadia Bessoltane ^d   Bellini, Angela ^d   Chicard, Mathieu ^d   Lapouble, Eve ^d   Combaret, Valérie ^e   Legoix Né, Patricia ^d   Michon, Jean ^d   Pugh, Trevor J ^f   Hart, Lori S ^b   Rader, Julieann ^b   Attiyeh, Edward F ^b,c   Wei, Jun S ^g   Zhang, Shile ^g   Naranjo, Arlene ^h   Gastier Foster, Julie M ^i,j   Hogarty, Michael D ^b,c   Asgharzadeh, Shahab ^k,l   Smith, Malcolm A ^m   Guidry Auvil, Jaime M ^m   Watkins, Thomas B K ⁿ   Zwijnenburg, Danny A ^a   Ebus, Marli E ^a   Van Sluis, Peter ^a   Hakkert, Anne ^a   Van Wezel, Esther ^a,o   Van Der Schoot, C Ellen ^a,o   Westerhout, Ellen M ^a   Schulte, Johannes H ^p,q,r   Tytgat, Godelieve A ^a   Dolman, M Emmy M ^a   Janoueix Lerosey, Isabelle ^s   Gerhard, Daniela S ^j   Caron, Huib N ^a   Delattre, Olivier ^s   Khan, Javed ^g   Versteeg, Rogier ^a   Schleiermacher, Gudrun ^d,s   Molenaar, Jan J ^a   Maris, John M ^b,c   more..

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d INSTITUT CURIE   (France)

^e CENTRE LÉON BÉRARD   (France)

^f PRINCESS MARGARET HOSPITAL   (Canada)

^g US National Institutes of Health   (United States)

^h UNIVERSITY OF FLORIDA   (United States)

ⁱ THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^j NATIONWIDE CHILDREN S HOSPITAL   (United States)

^k CHILDREN S HOSPITAL LOS ANGELES   (United States)

^l UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^m NATIONAL CANCER INSTITUTE   (United States)

ⁿ IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^o SANQUIN RESEARCH   (Netherlands)

^p CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^q German Consortium for Translational Cancer Research (DKTK)   (Germany)

^r UNIVERSITY HOSPITAL ESSEN   (Germany)

^s INSTITUT CURIE   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BINIMETINIB; COBIMETINIB; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN P14; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE PHOSPHATASE SHP 2; RAS PROTEIN; TRAMETINIB; ANAPLASTIC LYMPHOMA KINASE; BENZIMIDAZOLE DERIVATIVE; CYCLIN DEPENDENT KINASE INHIBITOR 2A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER RECURRENCE; CANCER RESISTANCE; CELL CYCLE ARREST; CHROMOSOME ABERRATION; CLINICAL ARTICLE; CLONAL EVOLUTION; CONTROLLED STUDY; DNA SEQUENCE; ENZYME ACTIVATION; ENZYME INHIBITION; FEMALE; GENE EXPRESSION; GENE MUTATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENOME ANALYSIS; GROWTH INHIBITION; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NEUROBLASTOMA; NEUROBLASTOMA CELL LINE; NONHUMAN; ONCOGENE RAS; OUTCOME ASSESSMENT; PHENOTYPIC VARIATION; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SENSITIVITY ANALYSIS; SIGNAL TRANSDUCTION; SOMATIC MUTATION; ANIMAL; CHILD; DRUG EFFECTS; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; HEK293 CELL LINE; INFANT; MALE; METABOLISM; MUTATION; PATHOLOGY; PHOSPHORYLATION; PRESCHOOL CHILD; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCID MOUSE; TUMOR CELL LINE; TUMOR RECURRENCE; WESTERN BLOTTING;

ANIMALS; BENZIMIDAZOLES; BLOTTING, WESTERN; CELL LINE, TUMOR; CHILD; CHILD, PRESCHOOL; CHROMOSOME ABERRATIONS; CYCLIN-DEPENDENT KINASE INHIBITOR P16; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEK293 CELLS; HUMANS; INFANT; MALE; MAP KINASE SIGNALING SYSTEM; MICE, SCID; MITOGEN-ACTIVATED PROTEIN KINASES; MUTATION; NEOPLASM RECURRENCE, LOCAL; NEUROBLASTOMA; PHOSPHORYLATION; RAS PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84938268035     PISSN: 10614036     EISSN: 15461718     Source Type: Journal    
DOI: 10.1038/ng.3333     Document Type: Article

References (43)

1. Hero, B. et al. Localized infant neuroblastomas often show spontaneous regression: Results of the prospective trials NB95-S and NB97. J. Clin. Oncol. 26, 1504-1510 (2008).
2. Park, J.R. et al. Children's Oncology Group's 2013 blueprint for research: Neuroblastoma. Pediatr. Blood Cancer 60, 985-993 (2013).
3. Simon, T. et al. Treatment and outcomes of patients with relapsed, high-risk neuroblastoma: Results of German trials. Pediatr. Blood Cancer 56, 578-583 (2011).
4. Maris, J.M. Recent advances in neuroblastoma. N. Engl. J. Med. 362, 2202-2211 (2010).
5. Cohn, S.L. et al. The International Neuroblastoma Risk Group (INRG) classification system: An INRG Task Force report. J. Clin. Oncol. 27, 289-297 (2009).
6. Bown, N. et al. Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma. N. Engl. J. Med. 340, 1954-1961 (1999).
7. Attiyeh, E.F. et al. Chromosome 1p and 11q deletions and outcome in neuroblastoma. N. Engl. J. Med. 353, 2243-2253 (2005).
8. Seeger, R.C. et al. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N. Engl. J. Med. 313, 1111-1116 (1985).
9. Caron, H. et al. Allelic loss of chromosome 1p as a predictor of unfavorable outcome in patients with neuroblastoma. N. Engl. J. Med. 334, 225-230 (1996).
10. Cheung, N.K. et al. Association of age at diagnosis and genetic mutations in patients with neuroblastoma. J. Am. Med. Assoc. 307, 1062-1071 (2012).
11. Molenaar, J.J. et al. Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes. Nature 483, 589-593 (2012).
12. Pugh, T.J. et al. The genetic landscape of high-risk neuroblastoma. Nat. Genet. 45, 279-284 (2013).
13. Sausen, M. et al. Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma. Nat. Genet. 45, 12-17 (2013).
14. Taggart, D., Dubois, S. & Matthay, K.K. Radiolabeled metaiodobenzylguanidine for imaging and therapy of neuroblastoma. Q. J. Nucl. Med. Mol. Imaging 52, 403-418 (2008).
15. Schleiermacher, G. et al. Emergence of new ALK mutations at relapse of neuroblastoma. J. Clin. Oncol. 32, 2727-2734 (2014).
16. Carter, S.L. et al. Absolute quantification of somatic DNA alterations in human cancer. Nat. Biotechnol. 30, 413-421 (2012).
17. Boca, S.M., Kinzler, K.W., Velculescu, V.E., Vogelstein, B. & Parmigiani, G. Patientoriented gene set analysis for cancer mutation data. Genome Biol. 11, R112 (2010).
18. Futreal, P.A. et al. A census of human cancer genes. Nat. Rev. Cancer 4, 177-183 (2004).
19. Bresler, S.C. et al. ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma. Cancer Cell 26, 682-694 (2014).
20. Hölzel, M. et al. NF1 is a tumor suppressor in neuroblastoma that determines retinoic acid response and disease outcome. Cell 142, 218-229 (2010).
21. Tartaglia, M. et al. Diversity and functional consequences of germline and somatic PTPN11 mutations in human disease. Am. J. Hum. Genet. 78, 279-290 (2006).
22. Carr-Wilkinson, J. et al. High frequency of p53/MDM2/p14ARF pathway abnormalities in relapsed neuroblastoma. Clin. Cancer Res. 16, 1108-1118 (2010).
23. Garnett, M.J. et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 483, 570-575 (2012).
24. Schleiermacher, G. et al. Accumulation of segmental alterations determines progression in neuroblastoma. J. Clin. Oncol. 28, 3122-3130 (2010).
25. Landau, D.A. et al. Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell 152, 714-726 (2013).
26. Long, G.V. Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma. Nat. Commun. 5, 5694 (2014).
27. George, R.E. et al. Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature 455, 975-978 (2008).
28. Mossé, Y.P. et al. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: A Children's Oncology Group phase 1 consortium study. Lancet Oncol. 14, 472-480 (2013).
29. Berry, T. et al. The ALKF1174L mutation potentiates the oncogenic activity of MYCN in neuroblastoma. Cancer Cell 22, 117-130 (2012).
30. Moore, N.F. et al. Molecular rationale for the use of PI3K/AKT/mTOR pathway inhibitors in combination with crizotinib in ALK-mutated neuroblastoma. Oncotarget 5, 8737-8749 (2014).
31. Drmanac, R. et al. Human genome sequencing using unchained base reads on self-assembling DNA nanoarrays. Science 327, 78-81 (2010).
32. Favero, F. et al. Sequenza: Allele-specific copy number and mutation profiles from tumor sequencing data. Ann. Oncol. 26, 64-70 (2015).
33. Krzywinski, M. et al. Circos: An information aesthetic for comparative genomics. Genome Res. 19, 1639-1645 (2009).
34. Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25, 1754-1760 (2009).
35. McKenna, A. et al. The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 20, 1297-1303 (2010).
36. Cibulskis, K. et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat. Biotechnol. 31, 213-219 (2013).
37. Wang, K., Li, M. & Hakonarson, H. ANNOVAR: Functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 38, e164 (2010).
38. 1000 Genomes Project Consortium. An integrated map of genetic variation from 1, 092 human genomes. Nature 491, 56-65 (2012).
39. Rausch, T. et al. DELLY: Structural variant discovery by integrated paired-end and split-read analysis. Bioinformatics 28, i333-i339 (2012).
40. Carter, S.L. et al. Absolute quantification of somatic DNA alterations in human cancer. Nat. Biotechnol. 30, 413-421 (2012).
41. Roth, A. et al. PyClone: Statistical inference of clonal population structure in cancer. Nat. Methods 11, 396-398 (2014).
42. Lamers, F. et al. Targeted BIRC5 silencing using YM155 causes cell death in neuroblastoma cells with low ABCB1 expression. Eur. J. Cancer 48, 763-771 (2012).
43. Gnirke, A. et al. Solution hybrid selection with ultra-long oligonucleotides for massively parallel targeted sequencing. Nat. Biotechnol. 27, 182-189 (2009).